製品の概要

  • 製品名Anti-ITM2B antibody
    ITM2B 一次抗体 製品一覧
  • 製品の詳細
    Goat polyclonal to ITM2B
  • アプリケーション適用あり: WBmore details
  • 種交差性
    交差種: Human
    交差が予測される動物種: Mouse, Rat, Cow
  • 免疫原

    Synthetic peptide:

    HDKETYKLQRRETIK

    , corresponding to internal sequence amino acids 224-238 of Human ITM2B (NP_068839.1).

  • ポジティブ・コントロール
    • Human Hippocampus lysate

製品の特性

アプリケーション

Our Abpromise guarantee covers the use of ab92284 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
WB
  • 追加情報WB: Use at a concentration of 1 - 3 µg/ml. Predicted molecular weight: 30 kDa.


    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • ターゲット情報

    • 機能Functions as a protease inhibitor. Plays a role in APP processing regulating the physiological production of the beta amyloid peptide. Restricts docking of gamma-secretase to APP and access of alpha- and beta-secretase to their cleavage APP sequence.
    • 組織特異性Expressed in brain and in other tissues.
    • 関連疾患Defects in ITM2B are a cause of cerebral amyloid angiopathy ITM2B-related type 1 (CAA-ITM2B1) [MIM:176500]. A disorder characterized by amyloid deposition in the walls of cerebral blood vessels and neurodegeneration in the central nervous system. Cerebral amyloid angiopathy, non-neuritic and perivascular plaques and neurofibrillary tangles are the predominant pathological lesions. Clinical features include progressive mental deterioration, spasticity and muscular rigidity.
      Defects in ITM2B are a cause of cerebral amyloid angiopathy ITM2B-related type 2 (CAA-ITM2B2) [MIM:117300]; also known as heredopathia ophthalmo-oto-encephalica. A disorder characterized by amyloid deposition in the walls of the blood vessels of the cerebrum, choroid plexus, cerebellum, spinal cord and retina. Plaques and neurofibrillary tangles are observed in the hippocampus. Clinical features include progressive ataxia, dementia, cataracts and deafness.
    • 配列類似性Belongs to the ITM2 family.
      Contains 1 BRICHOS domain.
    • 翻訳後修飾The C-terminal part of the ectodomain is processed by furin and related proteases producing a secreted peptide of 4 to 5 kDa. For the ABRI and ADAN variants the C-terminal secreted peptide is larger and may produce amyloid fibrils responsible for neuronal dysfunction and dementia. The remaining part of the ectodomain containing the BRICHOS domain is cleaved by ADAM10 and is secreted as a peptide of 25 kDa. The membrane-bound N-terminal fragment (NTF) of 22 kDa is further proteolytically processed by SPPL2A and SPPL2B through regulated intramembrane proteolysis producing a secreted peptide (BRI2C) and an intracellular domain (ICD) released in the cytosol.
    • 細胞内局在Golgi apparatus membrane. Cell membrane.
    • Information by UniProt
    • 参照データベース
    • 別名
      • ABRI antibody
      • ABri/ADan amyloid peptide antibody
      • BRI 2 antibody
      • BRI antibody
      • BRI2 antibody
      • BRICD 2B antibody
      • BRICD2B antibody
      • BRICHOS domain containing 2B antibody
      • E25B antibody
      • E3 16 antibody
      • E3-16 antibody
      • FBD antibody
      • Integral membrane protein 2B antibody
      • ITM 2B antibody
      • ITM2B antibody
      • ITM2B_HUMAN antibody
      • Protein E25B antibody
      • Transmembrane protein BRI antibody
      see all

    Anti-ITM2B antibody 画像

    • Anti-ITM2B antibody (ab92284) at 1 µg/ml + Human Hippocampus lysate at 35 µg
      Developed using the ECL technique

      Predicted band size : 30 kDa
      Observed band size : 30 kDa

    Anti-ITM2B antibody (ab92284) 使用論文

    ab92284 has not yet been referenced specifically in any publications.

    Product Wall

    There are currently no Abreviews or Questions for ab92284.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"